Ingenza
VC Fund
Edinburgh, United Kingdom
Ingenza is a VC fund in Edinburgh focused on Medical and Health Care. Ingenza was founded in 2002, a spin-out company from the University of Edinburgh that was based on the modification and commercialisation of microbial production technologies aimed at improving yields of unnatural amino acids and amines. Since its inception, Ingenza has remained strongly committed to the continuous development and integration ofinnovative technologies in its core competencies of molecular biology, gene expression, directed evolution, fermentation and process development.Ingenza is a world leader in the application of industrial biotechnology and synthetic biology, providing efficient, scalable bioprocesses for the manufacture of chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ingenza invests in
Stages Ingenza invests in
Countries Ingenza invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ian Fotheringham
|
|||
Jaymin Amin
|
|||
Sinil Srivastava
|
|||
2 more contacts available
Investment Focus
Industry
- Medical 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
Stage
- Seed 1 (33%)
- Funding Round 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ian Fotheringham
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Jaymin Amin
COO
|
COO | Total investments: 0 | Find email | |
|
Sinil Srivastava
Co-Founder and Chief Executive Officer
|
Co-Founder and Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ProFactor Pharma
|
Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophiliapatients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens. | $166K / Jun 01, 2016 | |
|
ProFactor Pharma
|
Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophiliapatients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens. | $120K / Mar 21, 2015 | |
|
ProFactor Pharma
|
Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophiliapatients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens. | $786K / Seed / Aug 31, 2013 |
Co-Investors
Kelvin Capital
3 deals together
Scottish Enterprise
2 deals together
Lancaster Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ingenza invest in?
Ingenza invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ingenza?
Public channels for Ingenza include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ingenza?
The team at Ingenza includes Ian Fotheringham (Managing Director), Jaymin Amin (COO) and Sinil Srivastava (Co-Founder and Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
